

Viral core protein inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/VDD22A6C99A0EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: VDD22A6C99A0EN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Viral core protein inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Viral core protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Viral core protein inhibitors Understanding

Viral core protein inhibitors: Overview

The core or capsid protein is essential to virion assembly and structure, interacts with several host cell proteins, and is the most conserved of all of the viral proteins across the six major genotypes. The core protein oligomerizes during the process of viral assembly, and a screen evaluating dimerization, a process mediated by the N-terminal domain, identified small-molecule inhibitors from a library of indoline derivatives. Core inhibitors, also known as capsid assembly modulators or core protein allosteric modulators, are a novel class of HBV replication inhibitors that have been shown to act at multiple steps in the HBV lifecycle.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Viral core protein inhibitors R&D. The therapies under development are focused on novel approaches for Viral core protein inhibitors.

Viral core protein inhibitors Emerging Drugs Chapters

This segment of the Viral core protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Viral core protein inhibitors Emerging Drugs

Vebicorvir: Assembly Biosciences

Vebicorvir, first-generation core inhibitor is being developed by Assembly Biosciences. In Phase 2 clinical trials, first-generation core inhibitor vebicorvir (VBR) administered with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy demonstrated a favorable safety profile and led to greater viral suppression of both HBV DNA and HBV pgRNA than NrtI therapy alone. VBR is advancing in multiple Phase 2 combination studies. Vebicorvir have been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of chronic HBV infection.

Morphothiadine: HEC Pharm

Morphothiadine (GLS4), a HAP (heteroaryl-di-hydro-pyrimidines) compound is being developed by HEC Pharm Group, for the oral treatment of hepatitis B.

Further product details are provided in the report.....

Viral core protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Viral core protein inhibitors drugs segregated based on following parameters that define the scope of the

report, such as:

Major Players working on Viral core protein inhibitors

There are approx. 5+ key companies which are developing the Viral core protein inhibitors. The companies which have their Viral core protein inhibitors drug candidates in the most advanced stage, i.e. Phase II include, Assembly Biosciences.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Viral core protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Viral core protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Viral core protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Viral core protein inhibitors drugs.

Viral core protein inhibitors Report Insights

Viral core protein inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Viral core protein inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Viral core protein inhibitors drugs?

How many Viral core protein inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Viral core protein inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Viral core protein inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Viral core protein inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Assembly Biosciences

HEC Pharm

Janssen Sciences Ireland

Enanta Pharmaceuticals

Fujian Cosunter Pharmaceutical

Door Pharmaceuticals

Key Products

Vebicorvir

GLS4

Bersacapavir

EDP 514

GST HG141

ABI H3733

ABI 4334

Research programme: HBV core protein modulators

Contents

Introduction

Executive Summary

Viral core protein inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Viral core protein inhibitors – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Vebicorvir: Assembly Biosciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I and I/II)

Comparative Analysis

EDP 514: Enanta Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis
ABI 4334: Assembly Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Viral core protein inhibitors Key Companies
Viral core protein inhibitors Key Products
Viral core protein inhibitors- Unmet Needs
Viral core protein inhibitors- Market Drivers and Barriers
Viral core protein inhibitors- Future Perspectives and Conclusion
Viral core protein inhibitors Analyst Views
Viral core protein inhibitors Key Companies
Appendix
Introduction
Executive Summary
Viral core protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Viral core protein inhibitors – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Mid Stage Products (Phase II)

Comparative Analysis
Vebicorvir: Assembly Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Early Stage Products (Phase I and I/II)
Comparative Analysis
EDP 514: Enanta Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Pre-clinical and Discovery Stage Products
Comparative Analysis
ABI 4334: Assembly Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Viral core protein inhibitors Key Companies
Viral core protein inhibitors Key Products
Viral core protein inhibitors- Unmet Needs
Viral core protein inhibitors- Market Drivers and Barriers
Viral core protein inhibitors- Future Perspectives and Conclusion
Viral core protein inhibitors Analyst Views
Viral core protein inhibitors Key Companies
Appendix

I would like to order

Product name: Viral core protein inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/VDD22A6C99A0EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VDD22A6C99A0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970